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1- Introduction 
The family of p38 mitogen-activated protein kinases 
(MAPKs) belongs to the MAPK superfamily. They are 
strongly activated by different stress signals and 
inflammatory cytokines, although non-stressful stimuli 
also activate p38 MAPKs leading to the regulation of 
cellular functions such as proliferation, differentiation 
and survival. Four different p38 MAPK family 
members have been identified so far: p38α, β, γ and δ, 
also known as stress-activated kinase 2a (SAPK2a), 
SAPK2b, SAPK3 and SAPK4, respectively, which may 
have both overlapping and specific functions (reviewed 
by Cuenda and Rousseau, 2007; Kyriakis and Avruch, 
2001; Nebreda and Porras, 2000; Ono and Han, 2000). 
p38α was initially identified as a 38 KDa protein, 
which became phosphorylated in Tyr in response to the 
bacterial endotoxin LPS in macrophages (Han et al., 
1994). In parallel, other two groups identified p38α as a 
kinase activated by stress and IL1, able to 
phosphorylate and activate MAPKAP-K2 (MAPK-
activated protein kinase 2) (Freshney et al., 1994; 
Rouse et al., 1994). p38α (encoded by MAPK14gene) is 
broadly expressed and is also the most abundant p38 
isoform present in most cell types. Targeted 
inactivation of the mouse p38α gene results in 
embryonic death due to a placental defect (Adams et 
al., 2000; Mudgett et al., 2000; Tamura et al., 2000). 
p38 MAPKs are mainly activated by MKK3 and 
MKK6 through dual phoshorylation in Tyr and Thr, 
although MKK4 can sometimes activate p38α (Cuenda 
and Rousseau, 2007).  
MKK3 and MKK6 are in turn activated by 
phosphorylation by a MAPK kinase kinase (MKKK) 
such as MLKs, ASK1, TAK1 or MEKKs, which are 
activated by small and heterotrimeric G proteins 
(Cuenda and Rousseau, 2007; Wagner and Nebreda, 
2009). 
p38α can be also activated through MKK-independent 
pathways such as that involving p38α 
autophospohorylation upon interaction with TAB1 
(Cuenda and Rousseau, 2007). 
Once p38 MAPKs are activated, they phoshorylate 
different transcription factors such as p53, ATF2, 
MEF2 or C/EBPb and protein kinases, including 
MAPKAP-K2 and MAPKAP-K3 (also known as MK-2 
and MK-3), MSK-1 (mitogen- and stress-activated 
protein kinase 1) and MNK-1 and MNK-2 (MAP 
kinase-interacting serine/threonine kinase 1 and 2) 
(Cuenda and Rousseau, 2007; Wagner and Nebreda, 
2009). 
The analysis of the function of p38α has been initially 
based on the effect of chemical inhibitors such as 
SB203580 and SB202190, which inhibit p38α but can 
also inhibit p38β at a higher dose (reviewed by 
Nebreda and Porras, 2000). Therefore, the main effects 
observed upon treatment with those inhibitors are a 
consequence of p38α inhibition, sometimes are also 
due to p38β inhibition. The generation of mice with 
specific genetic inactivation of the different p38 
isoforms or the use of interference RNA technology 
during the last few years has allowed a more precise 
study of the role played by each isoform and they have 
been essential to establish the role of p38α in different 
cellular processes. 
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 Figure 1. p38 MAPK signaling pathway. A variety of stimuli, mainly stress stimuli, activate p38 MAPK through complex kinase 
cascades including a MAP3K that phosphorylates a MAPK2 that, in turn, phosphorylates p38MAPKs. Cellular intermediates, like 
GTPases, receptor adapter proteins or cell cycle checkpoint proteins, among others, transmit the stimulus to the kinase cascades. Once 
activated, the different p38MAPKs either phosphorylate cytoplasmic targets or translocate into the nucleus leading to the regulation of 
transcription factors involved in cellular responses. MKK6 is the major activator of all p38 MAPK isoforms, while MKK3 and MKK4 are 
more specific and can only activate some isoforms. 
  
2- Dual role of p38 MAPK in cell 
death: function of p38α in apoptosis 
p38 MAPK can play a dual role as a regulator of cell 
death, thus it can either mediate cell survival or cell 
death through different mechanisms, including 
apoptosis. Therefore, the specific function of p38 
MAPKs in apoptosis appears to depend on the cell 
type, the stimuli and/or the isoform (reviewed by 
Nebreda and Porras, 2000; Wagner and Nebreda, 
2009). 
As indicated above, some studies have been based on 
the using of chemical inhibitors such as SB203580 
which is able to inhibit p38α and p38β, thus the 
participation of the p38β isoform in apoptosis can not 
be excluded. In fact, there is a good evidence for a role 
of p38α and/or p38β MAPKs as mediators of apoptosis 
in several cell types such as neurons (Ciesielski-Treska 
et al., 2001; De Zutter and Davis, 2001; Ghatan et al., 
2000; Le-Niculescu et al., 1999) or cardiac cells 
(Mackay and Mochly-Rosen, 1999; Saurin et al., 2000; 
Wang et al., 1998). Moreover, the induction of 
apoptosis by many types of stimuli such TNF-
α(Valladares et al., 2000), TGF-β (Edlund et al., 2003) 
or oxidative stress (Zhuang et al., 2000) involves one of 
these p38MAPKs. 
p38α is a mediator of apoptosis in response to a number 
of cellular stresses through transcriptional and 
posttranscriptional mechanisms, which can involve the 
regulation of apoptotic and/or survival pathways 
(reviewed by Wagner and Nebreda, 2009).  
For example, p38α sensitizes cardiomyocytes and 
MEFs-derived cell lines to apoptosis induced by 
different stimuli through both, up-regulation of the pro-
apoptotic proteins Fas and Baxand down-regulation of 
the activity of ERKs and Akt survival pathways (Porras 
et al., 2004; Zuluaga et al., 2007a). According to this, 
overexpression of p38α enhances apoptosis induced by 
the constitutive active mutant MKK3bE in 
cardiomyocytes, while overexpression of p38β 
promotes cell survival (Nebreda and Porras, 2000). 
p38α is also a negative regulator of survival in 
embryonic stem (ES) (Guo and Yang, 2006). In 
addition, p38α is able to suppress tumor initiation 
induced by H-rasoncogene through induction of 
apoptosis (Dolado et al., 2007). Upon expression of 
oncogenic H-Ras, ROS are generated leading to p38α 
activation and apoptotic cell death.  
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Moreover, p38α MAPK plays an important role in the 
apoptosis induced by some chemotherapeutical drugs. 
For example, it is essential for cisplatin-induced 
apoptosis in the colon carcinoma derived cell line, 
HCT116 (Bragado et al., 2007). 
On the other hand, anti-apoptotic roles of p38 MAPKs 
have been described in DNA-damaged fibroblasts 
(Héron-Milhavet and LeRoith, 2002), differentiating 
neurons (Okamoto et al., 2000) and activated 
macrophages (Park et al., 2002). In some cases, p38α 
has been identified as the isoform responsible for this 
survival effect. For example, in pulmonary arterial 
endothelial cells exposed to anoxia-reoxygenation 
during ischemia-reperfusion, carbon monoxide (CO) 
protects from apoptosis through p38α activation (Zhang 
et al., 2003; Zhang et al., 2005). In response to H2O2, 
p38α also mediates cell survival in MEFs, while p38α 
mediates apoptosis triggered by serum deprivation 
(Gutiérrez-Uzquiza et al., 2010). In both situations, 
C3G acts as a negative regulator of p38α. This 
crosstalk between the C3G and the p38α pathways has 
been also observed in CML cell line K562, where p38α 
mediates STI-571-induced apoptosis (Maia et al., 
2009). 
In contrast to the apoptotic role of p38 in CML cells 
treated with STI-571, p38 MAPK pathway exerts an 
antiapoptotic role in CML cells, as well as acute 
promyelocytic leukemia cells (APL), treated with 
arsenic trioxide (AT) (Verma et al., 2002b). 
In some tumor cells p38α can also induce a pro-
survival effect known as tumor dormancy, which 
maintains cells in a quiescent state related to drug 
resistance (reviewed by Aguirre-Ghiso, 2007). In 
addition, p38α can also induce cell survival of 
colorectal cancer cells through inhibition of autophagy 
(Comes et al., 2007). 
3- Pathways regulating p38α 
apoptotic function 
There are different signaling pathways that are 
involved in the regulation of p38 apoptotic function. 
Some of them can be considered classical and/or 
canonical, while others such as C3G-Rap1 or PKC are 
novel or less known. 
Classically, two small GTPases from the Rho family, 
Rac1 and Cdc42, have been described to be activators 
of p38α MAPK (Nobes and Hall, 1995). The existence 
of a functional crosstalk between Rac and p38 MAPK 
has been largely reported in relation with different 
cellular functions. p38 can act either as an effector or as 
an activator of Rac. In particular, in cardiomyocytes 
p38α acts as a positive or a negative regulator of Rac1 
depending on the presence of growth factors (Zuluaga 
et al., 2007b). On the other hand, Rac-GTP induces p38 
activation in many systems (Nobes and Hall, 1995). For 
example, Rac-1 is an upstream regulator of p38 in 
retinoic acid-induced differentiation and apoptosis of 
malignant NB-4 (acute pro-myelocytic leukemia) and 
MCF-7 (breast carcinoma) cell lines (Alsayed et al., 
2001). 
Recent novel findings support the participation of 
another member of the Ras family, the GTPase Rap1, 
in the regulation of p38α function in apoptosis 
(Gutiérrez-Uzquiza et al., 2010; Maia et al., 2009). 
Rap1 can either activate or inhibit p38α depending on 
the cell context. In CML cells, the C3G-Rap1 pathway 
downregulates the pro-apoptotic activity of 
p38αMAPK as a mediator of STI effects (Maia et al., 
2009). In contrast, in MEFs C3G is a negative regulator 
of p38α MAPK activity and Rap1 a positive one, 
leading to pro- or anti-apoptotic effects depending on 
the stress stimulus (Gutiérrez-Uzquiza et al., 2010). 
There are also evidences of a cross-talk between PKCs 
and p38 MAPK in order to regulate apoptosis. For 
example, in LNCaP prostate cancer cells, PMA induces 
apoptosis through a mechanism, which involves PKCα 
and d-mediated p38α/β activation (Tanaka et al., 2003). 
An autocrine pro-apoptotic loop is also generated in 
these cells by PKCδ, which is mediated by death 
receptor ligands through a mechanism dependent on 
caspase-8, FADD, p38α/β MAPK and JNK (Gonzalez-
Guerrico and Kazanietz, 2005). In addition, in vascular 
smooth muscle cells activation of PKCδ leads to 
apoptotic cell death involving p53 induction through a 
mechanism partially dependent on p38α/β MAPK 
(Ryer et al., 2005). 
4- Targets of p38α in the regulation 
of apoptosis 
The mechanisms by which p38α can mediate apoptosis 
or cell survival, include those involving the regulation 
of the expression and/or activity of different members 
of the Bcl-2 family. 
Bax is a pro-apoptotic member of the Bcl-2 family, 
which can be regulated by p38α through different 
mechanisms. In cardiomyocytes derived cell lines, 
p38α mediates an up-regulation of Bax mRNA and 
protein, which sensitizes cells to apoptosis induced by 
different stimuli (Porras et al., 2004). In addition, in 
primary neonatal cardiomyocytes p38 (α/β) mediates 
Bax translocation to mitochondria upon simulated 
ischemia (Capano and Crompton, 2006). This p38 
(α/β)-induced Bax translocation was also observed in a 
human hepatoma cell line (HepG2) treated with 
different pro-apoptotic stimuli (Kim et al., 2006). In 
contrast, in the anoikis-induced apoptosis in mammary 
epithelial cells, p38α is not required for Bax 
mitochondrial translocation, but it acts as a part of a 
mitochondrial complex allowing Bax activation and 
cytochrome-c release (Owens et al., 2009). 
Bimlevels (Cai and Xia, 2008) and activity (Cai et al., 
2006) are also positively regulated by p38α, which 
contributes to induce apoptosis. Thus, in PC12 cells 
treated with sodium arsenite, p38α induces 
FOXO3anuclear translocation, which stimulates Bim 
transcription, leading to an increase in BimEL protein 
levels (Cai and Xia, 2008). In addition, p38α 
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contributes to BimEL phosphorylation in Ser65 (Cai et 
al., 2006). 
Bcl-2 has been shown to be phosphorylated by p38α 
upon NGF withdrawal in memory B lymphocytes, 
which leads to inhibition of its anti-apoptotic activity 
and to induction of cytochrome-c release (Torcia et al., 
2001). Similarly, H2O2 induces p38α-mediated Bcl-2 
phoshorylation in adult rat cardiac myocytes 
contributing to apoptosis (Markou et al., 2009). 
p38 can also mediate survival through regulation of the 
expression and/or activity of proteins from the Bcl-2 
family. For example, carbon monoxide protects from 
ischemia-reperfusion lung injury through a p38α-
dependent up-regulation of Bcl-2 and Bcl-xLprotein 
levels (Zhang et al., 2003). According to this, UVA-
induced p38 (α/β) activation in a human keratinocyte 
cell line (HaCaT cells) results in an increase in Bcl-xL 
protein levels through post-transcriptional mechanisms 
mediated by the 3'-unstranslated region (UTR) 
(Bachelor and Bowden, 2004). In addition, in primary 
human trophoblasts p38 appears to mediate EGF-
mediated Bad phosphorylation in Ser 112, which 
protects from hypoxia-induced apoptosis (Humphrey et 
al., 2008). 
p38α is also involved in the stimulation of Fas and 
FasL expression, which can contribute to apoptosis in a 
number of cellular systems. p38α was shown to 
participate in the anti-CD3-induced upregulation of Fas 
and FasL expression in T cells, although p38α alone 
was unable to increase Fas expression (Hsu et al., 
1999). Similarly, p38 MAPK is a mediator of hepatitis 
B virus X protein-induced Fas and FasL expression 
(Wang et al., 2004). p38α activation also mediates Fas 
expression through phosphorylation of STAT1 in Ser-
727 in cardiac myocytes exposed to 
ischemia/reperfusion (Stephanou et al., 2001). 
According to this, Fas expression is down-regulated in 
p38α-deficient embryonic cardiomyocytes under basal 
conditions which contributes to sensitize cells to 
apoptosis (Porras et al., 2004). In contrast, p38 
downregulates Fas expression through inhibition of 
NF-kB in human melanoma cells (Ivanov and Ronai, 
2000). 
Apart from the role of p38α in the regulation of 
Fas/FasL expression, p38α mediates caspase 8 
activation in Fas-activated Jurkat cells by inhibiting the 
phoshorylation and presence of c-FLIPs in the DISC 
(Tourian et al., 2004). p38 also mediates TGF-β-
induced activation of caspase 8 (Schrantz et al., 2001) 
as well as the regulation of membrane blebbing and 
nuclear condensation (Deschesnes et al., 2001). 
The tumor suppressor protein p53, which is a relevant 
mediator of apoptosis in response to a great variety of 
stimuli, is also an important p38 target. In fact, there 
are a number of evidences supporting a role for p38α in 
the regulation of p53. For example, in response to 
different chemotherapeutic drugs such as cisplatin p38α 
phoshorylates and/or activates p53 leading to onset of 
apoptosis (Bragado et al., 2007; Sánchez-Prieto et al., 
2000). p38α can also induce apoptosis through p53 in 
response to other stimuli,. Thus, p53 phosphorylation 
by p38α is essential in the apoptosis induced by the 
HIV-1 envelope (Perfettini et al., 2005). In addition to 
this role of p38α as a direct regulator of p53, p38α also 
acts through phosphorylation and stabilization of the 
p53 coactivator, p18Hamlet (Cuadrado et al., 2007). In 
response to DNA damage p18Hamlet is accumulated, 
which contributes to induce apoptosis through the 
stimulation of some p53-regulated genes, such as Noxa. 
Other alternative mechanisms are involved in p38α-
mediated apoptosis. For example, phosphorylation of 
H2AX by p38α has been shown to be required for 
serum starvation-induced apoptosis (Lu et al., 2008). 
In addition to the above referred effects of p38α 
through direct regulation of pro- and/or antiapoptotic 
proteins, p38α is also a negative regulator of PI3K/Akt 
and ERKs survival pathways. Thus, in p38α-deficient 
derived cardiomyocytes or MEFs cell lines ERKs and 
Akt activities are increased, which contributes to the 
enhanced survival of these cells (Porras et al., 2004; 
Zuluaga et al., 2007a). In particular, in cardiomyocytes 
p38α can negatively modulate Akt activity, 
independently of PI3K, favoring the interaction 
between caveolin-1 and PP2A and the activation of 
PP2A through a mechanism dependent on cell 
attachment (Zuluaga et al., 2007a). 
There are additional mechanisms that can be involved 
in the p38α-induced survival, such as the activation of 
the ATF6α-Rheb-mTOR survival pathway (Schewe 
and Aguirre-Ghiso, 2008). Other mechanisms include 
the p38α mediated induction of antioxidant enzymes 
expression in response to oxidative stress (unpublished 
data from our group). In addition, the increase in BNIP-
3 levels and the low Bim/Bcl-xL ratio induced by p38α 
would contribute to this survival effect upon H2O2 
treatment (Gutiérrez-Uzquiza et al., 2010). 
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 Figure 2. Mechanisms involved in p38α-mediated apoptosis. p38Î± induces the expression of pro-apoptotic proteins such as the 
death receptor, Fas and its ligand, FasL, as well as Bax, Bim or Noxa from the Bcl-2 family. This expression is induced by the 
phosphorylation of transcription factors, such as p53 and/or coactivators such as p18Hamlet. This would lead to the activation of the Fas 
death receptor pathway and the mitochondrial pathway. p38α can also activate some of these pro-apoptotic proteins, such as Bim, 
through phosphorylation or through alternative mechanisms as it happens for Bax. Alternatively, p38α can inhibit c-FLIP phosphorylation 
impairing its function as an inhibitor of caspase 8 activation. p38α can also inactivate the anti-apoptotic protein Bcl-2 through 
phosphorylation. In addition, p38α negatively regulates ERKs and Akt survival pathways, being PP2A the mediator of Akt inactivation. 
  
5- Disregulation of p38α function in 
apoptosis: involvement in human 
diseases  
Different evidences from the literature indicate that the 
pro-apoptotic function of p38α is deregulated in some 
human diseases such as cancer, although recent 
findings have also linked p38 signaling with 
neurodegenerative diseases such as Alzheimer's disease 
(AD), Parkinson disease (PD) and amyolotrophic 
lateral sclerosis (ALS) (reviewed by Kim and Choi, 
2010). 
5.1- Role of p38α in cancer: implication in cancer 
development and therapy 
5.1.1- p38α as a tumor suppressor and/or mediator 
Several data indicate that p38α can act as a tumour 
suppressor (Review by Wagner and Nebreda, 2009). In 
particular, p38α negatively regulates malignant 
transformation induced by Ras through different 
mechanisms including apoptosis induction. For 
example, in MEFs expressing H-RasV12, sustained 
activation of p38α MAPK inhibits transformation 
through a mechanism involving ROS-induced 
apoptosis (Dolado et al., 2007). H-RasV12-induced 
ROS is only able to trigger apoptosis in MEFs 
expressing p38α, but not in those deficient in this 
protein. As a consequence, p38α-deficient MEFs 
transformed by Ras accumulate high levels of ROS 
which contributes to tumour progression. This type of 
response is produced in the transformation induced by 
different oncogenes able to generate ROS. In fact, 
many human cancer cell lines have developed 
mechanisms to uncouple ROS generation to p38α 
activation and therefore induction of apoptosis. 
However, as referred above, p38α can also induce a 
survival state known as tumor dormancy in some 
cancer cells such as those from squamous carcinoma, 
which maintains cells in a quiescent state related to 
drug resistance through mechanisms including 
activation of the p38α-ATF6α-Rheb-mTOR survival 
pathway (reviewed by Aguirre-Ghiso, 2007; Schewe 
and Aguirre-Ghiso, 2008). 
5.1.2- Role of p38 in chronic myeloid leukemia and 
other hematopoietic malignancies 
p38 MAPK, mainly the p38α isoform, is a key player in 
the maintenance of hematopoiesis homeostasis, as it 
balances both proliferative and growth inhibitory 
signals triggered by the growth factors and cytokines 
that regulate normal hematopoiesis (Feng et al., 2009; 
Uddin et al., 2004). Alterations in this p38 MAPK-
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controlled balance may result in either overproduction 
or depletion of myelosuppressive cytokines leading to 
the development of certain bone marrow failure 
syndromes. For example, p38α is responsible for the 
enhanced stem cell apoptosis characteristic of low 
grade myeolodysplastic syndromes (MDSs) (Navas et 
al., 2006; Zhou et al., 2007). On the other hand, 
imbalance toward the proliferative side may conduct to 
the development of myeloproliferative syndromes 
(MPSs), such as leukemia, lymphomas and myelomas. 
The role played by different members of the p38 kinase 
family in the regulation of acute leukemia blasts growth 
(myeloid and lymphoid), is not well defined, although 
they seem to participate in the generarion of resistance 
to chemotherapeutic agents (Feng et al., 2009; 
Platanias, 2003) In contrast, the participation of the p38 
MAPK pathways in the pathogenesis and 
pathophysiology of chronic leukemias have been 
extensively studied, although its role is contradictory. 
On one side, p38 is activated by the Rho-GEF domain 
of Bcr, contributing to transformation through the 
regulation of NF-κB activation (Korus et al., 2002). On 
the other side, p38 MAPK is selectively activated by 
IFNα and mediates the growth suppressive effects of 
IFNα in CML cells (Mayer et al., 2001) as well as in 
normal hematopoiesis (Verma et al., 2002a). 
p38 MAPK also seems to play a role in chronic 
lymphocytic leukemia(CLL). p38 and its effector MK-
2 (MAP kinase-activated protein kinase-2) are activated 
by rituximab in cultures of CLL cells and contributes to 
the generation of the antileukemic effects of rituximab 
in CLL (Pedersen et al., 2002). Finally, there are 
evidences supporting the participation of p38 in cell 
proliferation and adhesion of lymphomas and multiple 
myelomas in response to growth factors (Feng et al., 
2009; Platanias, 2003). 
Another important function of p38α MAPK in 
hematopoiesis is to promote cell differentiation. 
Curiously, while GTP-induced erythroid differentiation 
of K562 cells is mediated through p38-dependent 
caspase activation (Moosavi et al., 2007), caspases do 
not participate in STI-571-induced erythroid 
differentiation in CML cells, where STI-571-mediated 
apoptosis and differentiation are independent events 
(Jacquel et al., 2007). The differentiation-inducing 
therapy may be a good therapeutical alternative for 
CML patients that develop resistance to STI-571. 
5.2- Role of p38α in neurodegenerative diseases 
Recent findings support the involvement of p38 MAPK 
signaling pathway in neurodegenerative diseases. Thus, 
persistent activation of the p38 MAPK signaling has 
been suggested to contribute to neuronal apoptosis in 
Alzheimer's disease (AD), Parkinson disease(PD) and 
Amyotrophic lateral sclerosis (ALS). 
Alzheimer's disease is an incurable, neurodegenerative 
disease characterized by a progressive deterioration of 
the congnitive, memory and learning ability including 
lost of motor coordination at advanced stages. AD is 
the result of the accumulation of plaques containing 
amyloidogenic Aβ proteins and tangles containing the 
microtubule-associated protein tau in a 
hiperphosphorylated state (Giacobini and Becker, 
2007). The ASK1-MKK6-p38 signaling pathway 
participates in amyeloid precursor protein (APP) and 
tau phosphorylation in response to oxidative stress and 
contributes to the expression of the β-secretase gene 
(Galvan et al., 2007) and the induction of neuronal 
apoptosis triggered by ROS (D'Amico et al., 2000; Puig 
et al., 2004; Tamagno et al., 2003). 
Parkinson disease is a degenerative disorder of the 
central nervous system characterized by muscle 
rigidity, tremor and loss of physical movement caused 
by a progressive loss of dopaminergic neurons. A 
number of specific genetic mutations causing 
Parkinson's disease have been discovered, being the 
mutations in α-Synuclein (a major constituent of Lewy 
bodies) among the best characterized (Gandhi and 
Wood, 2005). α-Synuclein activates p38 MAPK in 
human microglia promoting a potent inflammatory 
stimulation of microglial cells (Klegeris et al., 2008). 
The p38 MAPK is also activated in PD cellular and 
animal models and plays a role in dopaminergic neural 
apoptosis through the phosphorylation of p53 and 
expression of the pro-apoptotic protein Bax 
(Karunakaran et al., 2008; Mathiasen et al., 2004; Silva 
et al., 2005). 
Amyotrophic lateral sclerosis is a progressive, lethal, 
degenerative disorder of motor neurons in the brain and 
spinal cord, leading to paralysis of voluntary muscles. 
Aberrant chemistry and oxidative stress have been 
described to be involved in ALS development, being 
SOD1 (superoxide dismutase 1) the most frequently 
mutated gene in the inherited cases of ALS. Numerous 
evidences point to a role of p38 MAPK in the 
development and progression of ALS induced by 
mutations in SOD1 gene (Bendotti et al., 2004; 
Bendotti et al., 2005; Dewil et al., 2007; Holasek et al., 
2005; Tortarolo et al., 2003). Mutant SOD1 provokes 
aberrant oxyradical reactions that increase the 
activation of p38 MAPK in motor neurons and glial 
cells. This increase in active p38 MAPK may 
phosphorylate cytoskeletal proteins and activate 
cytokines and nitric oxide, thus contributing to 
neurodegeneration through different mechanisms 
including apoptosis (Bendotti et al., 2005; Tortarolo et 
al., 2003). 
5.3- p38α in cancer therapy 
p38α can act as a tumor suppressor in the initial phases 
of malignant transformation, which involves apoptosis 
induction.  
Similarly, p38α is also a mediator of apoptosis upon 
treatment with many chemotherapeutical drugs such as 
cisplatin, arsenic trioxide or others. Therefore, p38α 
can be considered as a target in the treatment of cancer, 
although sometimes is also responsible for the 
resistance to some of these treatments. 
It is well established that p38 MAPK mediates the 
responses to several DNA-damaging agents, such as 
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UV radiation, cisplatin (CDDP) and Ara-C through 
activation of p53-dependent and independent responses 
(Bulavin et al., 1999; Huang et al., 1997; Sánchez-
Prieto et al., 2000). Cisplatin is an anti-cancer drug that 
induces apoptosis in a number of cancer cell lines 
through mechanisms that in many cases are p38 
dependent. In the colon carcinoma cell line HCT116, 
the activation of p38α was shown to be necessary for 
CDDP-induced apoptosis, upon activation by p53-
mediated ROS production (Bragado et al., 2007). Once 
p38α MAPK is activated, it contributes to further 
activation of p53, which leads to a positive feedback 
loop. So, a p53/ROS/p38α MAPK cascade is essential 
for cisplatin-induced cell death and the subsequent 
p38α/p53 positive feedback loop strongly enhances the 
initial p53 activation in HCT116 cells. In other cancer 
cell lines, c-Abl is required for CDDP-induced p38 
activation and for its antitumoral effect. Thus, CDDP-
induced cell death appears to be dependent on c-Abl 
expression, rather than on its tyrosine kinase activity, 
and on stabilization of MKK6 protein levels (Galán-
Moya et al., 2008). This pro-apoptotic effect of CDDP 
is not selective for tumoral cells. Hence, in NIH3T3 
cells, which are non-transformed cells, an involvement 
of p38(α/β) MAPK was described as mediator of 
CDDP-induced apoptosis through a mechanism 
dependent on the phosphorylation of p53 in Ser33 and 
the subsequent p53 transcriptional activation (Sánchez-
Prieto et al., 2000). 
Similarly to CDDP, other anticancer drugs also lead to 
the generation of ROS as an important mechanism to 
induce apoptosis in cancer cells, being p38α a relevant 
mediator. Thus, diamine, a thiol-oxidizing compound, 
induces apoptosis in a gastric human 
adenocarcinomacell line (AGS) through a mechanism 
dependent on Trx1/p38α/p53 pathway, while CaCo2 
cells are resistant to this compound due to the absence 
of a functional p53 (Piccirillo et al., 2009). 
As previously mentioned, activation of p38 MAPK 
plays a key role in some hematopoietic malignancies by 
different mechanisms including increasing resistance to 
chemotherapeutic agents (Feng et al., 2009). Ara C is a 
classic anti-neoplasic agent widely used in the 
treatment of CML blast crisis, which provides a typical 
example of genotoxic stress mediated through c-Abl-
p38 MAPK pathway (Huang et al., 1997; Pandey et al., 
1996; Stadheim et al., 2000). Although p38 MAPK is 
activated by c-Abl in response to CDDP in some cancer 
cell lines (Galán-Moya et al., 2008) and by 
overexpression of Bcr-Abl, Ara-C (1-β-D-
arabinofuranosylcytosine) is unable to activate p38 
MAPK in cells with constitutive expression of Bcr-Abl 
such as the CML derived cell line K562 (Sánchez-
Arévalo Lobo et al., 2005). In those cells, Bcr-Abl 
induces a sustained activation of the p38 MAPK 
pathway (not related to increased apoptosis), rendering 
them insensitive to further activation in response to 
Ara-C. Therefore, Bcr-Abl mediated p38 MAPK 
activation is a key mechanism to explain resistance to 
Ara-C. In fact, lack of p38 MAPK activation is a 
general mechanism for Ara-C resistance, as it had been 
previously proposed (Stadheim et al., 2000). This could 
provide a clue for new therapeutic approaches based on 
the combined use of specific Abl and p38 MAPK 
inhibitors. 
In contrast, p38 MAPK signaling cascade mediates the 
antiproliferative effects of STI-571 (or imatinib, the 
current drug used in CML treatment) and cisplatin on 
Bcr-Abl expressing cells (Galán-Moya et al., 2008; 
Parmar et al., 2004). Moreover, we have recently found 
a functional relationship between C3G and p38 in 
CML, so that the pro-apoptotic activity of p38α 
MAPK, as a mediator of STI-571 effects, is 
downregulated by the C3G-Rap1 pathway and the 
antitumoral effects of STI-571 could be improved by 
C3G gene silencing as it enhances p38α activation and 
pro-apoptotic activity (Maia et al., 2009). 
In contrast, p38 appears to be a negative regulator of 
the antitumoral effects of all-trans-retinoic acid (RA), 
which induces differentiation and growth arrest in 
several malignant cell types, including acute 
promyelocytic leukemia (APL) and breast carcinoma. 
The Rac-p38 MAPK-MK2 pathway is activated by RA 
and negatively regulates RA-effects in NB-4 APL and 
MCF-7 breast cancer cell lines, as p38α/β inhibitor 
SB203580 enhances RA-dependent cell differentiation 
and apoptosis. Therefore, pharmacological inhibition of 
p38α/β may prevent resistance to RA that is developed 
in nearly all cases (Alsayed et al., 2001). 
Arsenic trioxide (AT), which also induces 
differentiation and apoptosis of leukemia cells in vitro 
and in vivo, activates the Rac-p38 MAPK-MK2 
pathway, which can act as a negative regulator of AT 
functions, suggesting a possible role of p38 MAPK 
pathways in AT-induced resistance (Verma et al., 
2002b). However, AT can sensitize human 
promonocytic cells U937 to TNF-α-induced apoptosis, 
which is dependent on p38α/β activation (Amran et al., 
2007). AT increases the levels of TNF-α receptor 
leading to an enhancement of TNF-α-induced 
apoptosis. 
The role of p38 MAPK in resistance to 
chemotherapeutic agents is also observed in an 
experimental model of head and neck cancer, where 
lower activation or lack of activation of p38 MAPK 
correlates with a more resistant phenotype (Losa et al., 
2003). 
Therefore, based on all these data described here and 
other published data, p38α would play a dual role in 
cancer treatment. Depending on the type of tumour and 
the chemotherapeutic agent, p38α can either induce 
apoptosis or survival, leading to the disappearance of 
the tumour or making it resistant to chemotherapy. 
Concluding remarks 
p38α MAPK (encoded by MAPK14 gene) is broadly 
expressed and is also the most abundant p38 isoform 
present in most cell types. It can be activated by several 
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extracellular signals, including stress stimuli, leading to 
the regulation of different cellular processes, which 
includes cell death. Although in many cases p38α is a 
mediator of apoptosis, recent data indicate that it can 
also have a pro-survival role. Therefore, p38α would 
play a dual role in apoptosis, which is dependent on the 
cell context and/or stimulus. 
p38α regulates apoptosis through transcriptional and 
posttranscriptional mechanisms, being of particular 
relevance the modulation of proteins from the Bcl-2 
family and proteins involved in the death receptor 
pathway such as Fas and FasL. 
p38α-mediated apoptosis or survival is deregulated in a 
number of pathologies. For example, some 
neurodegenerative diseases are linked to an enhanced 
apoptosis mediated by p38α. p38α can also act as a 
tumour suppressor in the initial stages of malignant 
transformation through activation of apoptosis. In 
addition, the antitumoral effects of a number of 
chemotherapeutical drugs are based on the activation of 
apoptosis through p38α. However, it should be notice 
that in some tumours p38α MAPK is involved in 
chemotherapeutical resistance. 
We apologize to the authors whose original work is not 
included in the references due to extension constrains. 
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